US Patent Issued to INSTITUTE FOR CANCER RESEARCH on March 1 for "Chimera of bone morphogenic protein 2 and the Mullerian-inhibiting substance type II receptor binding region of Mullerian-inhibiting substance" (Pennsylvania Inventors)

Press/Media

PeriodMar 1 2022

Media coverage

1

Media coverage

  • TitleUS Patent Issued to INSTITUTE FOR CANCER RESEARCH on March 1 for "Chimera of bone morphogenic protein 2 and the Mullerian-inhibiting substance type II receptor binding region of Mullerian-inhibiting substance" (Pennsylvania Inventors)
    Media name/outletUS Fed News
    Country/TerritoryUnited States
    Date03/1/22
    PersonsRoland Dunbrack
View all 1
View less